Primary high-risk HPV screening for cervical cancer in post-menopausal women

被引:51
|
作者
Gyllensten, Ulf [1 ]
Gustaysson, Inger
Lindell, Monica
Wilander, Erik
机构
[1] Uppsala Univ, Dept Immunol Genet & Pathol, Rudbeck Lab, SciLifeLab Uppsala, S-75185 Uppsala, Sweden
基金
瑞典研究理事会;
关键词
Cervix; Screening; Post-menopausal; High-risk HPV; CIN; ATYPICAL SQUAMOUS-CELLS; HUMAN-PAPILLOMAVIRUS; UNDETERMINED SIGNIFICANCE; CYTOLOGY; PERSISTENCE; TRENDS; SMEARS;
D O I
10.1016/j.ygyno.2012.01.036
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. The present study was conducted to examine the value of screening for high-risk HPV in post-menopausal women. Methods. A cohort of post-menopausal women (n =2113), age range 55-76 years, from Uppsala County, Sweden, were offered testing for both high-risk HPV and a Pap smear in the gynaecological screening during 2008-2010. For the HPV test the cervical smear sample was applied to a filter paper matrix, an indicating FTA elute card and HPV typing performed using a real-time PCR assay. Histological verified CIN2+ lesion was used as an end-point measurement. Results. High-risk HPV were found in 6.2% (95% CI 5.2-7.3%) of the women (n = 130) and 22% (95% CI 14-32%) (n = 17) of these had CIN2 + lesions based on histology. The Pap smear taken in conjunction with the HPV test was abnormal in 9.7% (95% CI 5.7-16.3%) (n = 12) of HPV positive women. Among HPV positive women with an abnormal Pap smear, the frequency of histology verified CIN2+ lesions was 67% (95% Cl 38-86%) (n = 8), as compared to 14% (95% CI 7-24%) (n = 9) in HPV positive women with a normal smear. The prevalence of HPV16 in CIN2+ lesions (29%, 95% CI 22-37%) in post-menopausal women was less than half of previous estimates in pre-menopausal women from this population. Conclusions. Most histological CIN2+ lesions in post-menopausal women are not recognized by a single Pap smear. A large fraction of pre-invasive cervical cancer cases in post-menopausal women result from infections by HPV types not included in the present vaccine formulas. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:343 / 345
页数:3
相关论文
共 50 条
  • [31] Utilization of PAX1 methylation test for cervical cancer screening of non-HPV16/18 high-risk HPV infection in women
    Yang, Li
    Tao, Hong
    Lin, Beibei
    He, Xiaoli
    Chen, Yibo
    Fan, Xing
    FUTURE ONCOLOGY, 2023, 19 (28) : 1917 - 1927
  • [32] Evaluation of Viral Load as a Triage Strategy With Primary High-Risk Human Papillomavirus Cervical Cancer Screening
    Luo, Hongxue
    Belinson, Jerome L.
    Du, Hui
    Liu, Zhihong
    Zhang, Lijie
    Wang, Chun
    Qu, Xinfeng
    Pretorius, Robert G.
    Wu, Ruifang
    JOURNAL OF LOWER GENITAL TRACT DISEASE, 2017, 21 (01) : 12 - 16
  • [33] Thinking Differently About Cervical Cancer Screening in High-Risk Populations
    Meyerson, Beth E.
    Crosby, Richard A.
    Van der Pol, Barbara J.
    Zimet, Gregory D.
    AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2012, 43 (02) : 221 - 224
  • [34] High-risk human papillomavirus in HIV-infected women undergoing cervical cancer screening in Lilongwe, Malawi: a pilot study
    Reddy, Deepa
    Njala, Joseph
    Stocker, Penny
    Schooley, Alan
    Flores, Martiniano
    Tseng, Chi-Hong
    Pfaff, Colin
    Jansen, Perry
    Mitsuyasu, Ronald T.
    Hoffman, Risa M.
    INTERNATIONAL JOURNAL OF STD & AIDS, 2015, 26 (06) : 379 - 387
  • [35] Risk of cervical lesions in high-risk HPV positive women with normal cytology: a retrospective single-center study in China
    Wang, Zhiling
    Liu, Ting
    Wang, Yunjian
    Gu, Ying
    Wang, Hui
    Liu, Jingkang
    Cui, Baoxia
    Yang, Xingsheng
    INFECTIOUS AGENTS AND CANCER, 2020, 15 (01)
  • [36] Risk factors for HPV infection and cervical cancer among unscreened women in a high-risk rural area of China
    Zhao, FH
    Forman, MR
    Belinson, J
    Shen, YH
    Graubard, BI
    Patel, AC
    Rong, SD
    Pretorius, RG
    Qiao, Y
    INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (02) : 442 - 448
  • [37] Primary HPV and Molecular Cervical Cancer Screening in US Women Living With Human Immunodeficiency Virus
    Strickler, Howard D.
    Keller, Marla J.
    Hessol, Nancy A.
    Eltoum, Isam-Eldin
    Einstein, Mark H.
    Castle, Philip E.
    Massad, L. Stewart
    Flowers, Lisa
    Rahangdale, Lisa
    Atrio, Jessica M.
    Ramirez, Catalina
    Minkoff, Howard
    Adimora, Adaora A.
    Ofotokun, Igho
    Colie, Christine
    Huchko, Megan J.
    Fischl, Margaret
    Wright, Rodney
    D'Souza, Gypsyamber
    Leider, Jason
    Diaz, Olga
    Sanchez-Keeland, Lorraine
    Shrestha, Sadeep
    Xie, Xianhong
    Xue, Xiaonan
    Anastos, Kathryn
    Palefsky, Joel M.
    Burk, Robert D.
    CLINICAL INFECTIOUS DISEASES, 2021, 72 (09) : 1529 - 1537
  • [38] Introduction of primary screening using high-risk HPV DNA detection in the Dutch cervical cancer screening programme: a population-based cohort study
    Aitken, Clare A.
    van Agt, Heleen M. E.
    Siebers, Albert G.
    van Kemenade, Folkert J.
    Niesters, Hubert G. M.
    Melchers, Willem J. G.
    Vedder, Judith E. M.
    Schuurman, Rob
    van den Brule, Adriaan J. C.
    van der Linden, Hans C.
    Hinrichs, John W. J.
    Molijn, Anco
    Hoogduin, Klaas J.
    van Hemel, Bettien M.
    de Kok, Inge M. C. M.
    BMC MEDICINE, 2019, 17 (01)
  • [39] The Value of TruScreen (An Artificial Intelligence Cervical Cancer Screening System) in High-Risk HPV Positive Patients
    Luo, Lianmei
    Zhang, Jun
    CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY, 2023, 50 (10):
  • [40] Update in treatment of early breast cancer in post-menopausal women
    Prince, Rebecca M.
    Amir, Eitan
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2016, 11 (03) : 243 - 252